Posted by Michael Wonder on 18 Jul 2021
UnitedHealth seeks more clarity on Biogen's $56,000 Alzheimer's drug coverage
16 July 2021 - UnitedHealth Group said it needed more time to determine its coverage policy for Biogen's recently approved $56,000 Alzheimer's disease drug Aduhelm that is expected to raise costs for the U.S. government Medicare program.
The Government's Medicare program and private health insurers such as UnitedHealth, which sell Medicare Advantage plans for those aged above 65 and are known to be susceptible to Alzheimer's disease, will be affected as they will have to bear most of the drug cost.
